RxDoctor Payments Data

Laura Pace

Gastroenterology · Stanford, CANPI 1104142025

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Mauna Kea Technologies, Inc. accounts for 85.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $1,552 and has fallen 89.9% since, to $157 in 2025.

$3,633in general payments, 2019–2025

Across 30 payments — averaging $121.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mauna Kea Technologies, Inc.$3K
  • Ionis Pharmaceuticals, Inc.$106
  • AbbVie$103
  • Fujifilm Healthcare Americas Corporation$95
  • Tersera Therapeutics LLC$87
  • Amgen$65
  • plus $70 from 3 others
$248,957in research payments, 2019–2025

Across 279 payments — averaging $892.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Argenx US, Inc.$231K
  • Vanda Pharmaceuticals Inc.$18K

What the payments were for

  • Consulting fees$1,00028%
  • Travel & lodging$79122%
  • Food & beverage$1,84251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,633 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California →

Medicare billing

Part B allowed, 2024
$12,432
Medicare patients
45
Services billed
106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Stanford

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →